GSK (GSK) reported Q4 core earnings Wednesday of 0.26 British pound ($0.36) per share, up from 0.23 pound a year earlier.
Analysts polled by FactSet expected 0.24 pound.
Sales for the quarter ended Dec. 31 were 8.62 billion pounds, up from 8.18 billion pounds a year earlier.
Analysts surveyed by FactSet expected 8.47 billion pounds.
For 2026, the pharmaceutical company expects core EPS to increase 7% to 9% and sales to increase 3% to 5%.
Shares were 1.8% higher in premarket trade Wednesday.